Trametinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 0.5 mg, 1 mg, 2 mg
Reference Brands: Mekinist (USA/EU)
Category: Oncology Cancer Care
Trametinib is a targeted cancer therapy that inhibits MEK1 and MEK2 enzymes in the MAPK/ERK pathway, helping to slow or stop the growth of cancer cells. It is primarily used for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations and can be combined with BRAF inhibitors for enhanced efficacy. Trametinib is available in Tablets and strengths such as 0.5 mg, 1 mg, 2 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Trametinib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Trametinib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Trametinib is used to treat certain cancers, including unresectable or metastatic melanoma with BRAF V600E or V600K mutations, and in combination with other drugs for some non‑small cell lung cancers, thyroid cancer, certain solid tumors, and glioma with specific mutations.
Trametinib is a small‑molecule MEK inhibitor that blocks the activity of MEK1 and MEK2 enzymes in the MAPK/ERK signaling pathway, which helps prevent cancer cells from multiplying.
The trade names are Mekinist and Spexotras.
It is manufactured and marketed by the companies holding the global marketing rights, including Novartis under the trade name Mekinist.
The generic name is trametinib.
Brand names include Mekinist and Spexotras.
Trametinib is produced as an oral drug in pharmaceutical manufacturing facilities under standard regulatory practices, available as tablets or oral solution depending on patient needs.
Related Products
Motixafortide Acetate
Strength:
1 mg/mL
Form: Injection
Reference Brands: Aphexda (USA)
View Details
Momelotinib
Strength:
100 mg, 150 mg, 200 mg
Form: Tablets
Reference Brands: Ojjaara (USA)
View Details
Nirogacestat
Strength:
50 mg
Form: Tablets
Reference Brands: Generic formulations marketed under different names
View DetailsQuick Response Guaranteed | Verified Suppliers
